Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(12;17)(p13;q11-21) in ALL

Written2006-04David Betts
Department of Oncology, University Children's Hospital, Steinwiesstr. 75, CH-8032 Zò_rich, Switzerland

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
ICD-Morpho 9811/3 B lymphoblastic leukaemia/lymphoma, NOS
Atlas_Id 1072

Clinics and Pathology

Disease Acute lymphoblastic leukaemia (ALL)
Note Identical or similar translocations have been reported rarely in acute myeloid leukemia (AML) and acute mixed lineage leukaemia ( t(12;17)(p13;q11-21) in AML ).
Phenotype / cell stem origin Most reports indicate an early pre-B immunophenotype, frequently characterised by low CD10 and positivity of the myeloid marker CD33.
Epidemiology Rare; non-random translocation that predominantly occurs in children and young adults. No definable sex bias.
Prognosis Early reports suggested that prognosis may be poor, but there are currently too few reported cases to define a robust association.

Cytogenetics

Cytogenetics Morphological The chromosome 17q breakpoint has been defined in different reports to be between q11-q21. The chromosome 12 breakpoint has been confirmed to be located in 12p13 telomeric to the ETV6/TEL locus. The translocation occurs as the sole or primary event in approximately 50% of cases
Additional anomalies No consistent picture and only +21 has been reported in more than one case.

Genes involved and Proteins

Note Breakpoint on 12p13 telomeric to TEL. Currently the genes involved on both chromosome 12 and 17 are unidentified.

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.
Krance RA, Raimondi SC, Dubowy R, Estrada J, Borowitz M, Behm F, Land VJ, Pullen J, Carroll AJ
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1992 ; 6 (4) : 251-255.
PMID 1534130
 
Translocation (12;17)(p11-12;q11-12): a recurrent primary rearrangement in acute leukemia.
Liu HW, Wan SK, Ching LM, Liang R, Chan LC
Cancer genetics and cytogenetics. 1992 ; 64 (1) : 27-29.
PMID 1458446
 
A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia.
Reid AG, Seppa L, von der Weid N, Niggli FK, Betts DR
Cancer genetics and cytogenetics. 2006 ; 165 (1) : 64-69.
PMID 16490598
 
Fluorescence in situ hybridization analysis of the cryptic t(12;21) (p13;q22) in childhood B-lineage acute lymphoblastic leukemia.
Yehuda-Gafni O, Cividalli G, Abrahmov A, Weintrob M, Neriah SB, Cohen R, Abeliovich D
Cancer genetics and cytogenetics. 2002 ; 132 (1) : 61-64.
PMID 11801311
 

Citation

This paper should be referenced as such :
Betts, D
t(12;17)(p13;q11-21) in ALL
Atlas Genet Cytogenet Oncol Haematol. 2006;10(4):261-261.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/t1217p13q21ALLID1072.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(12;17)(p13;q11) in ALL

External links

Mitelman databaset(12;17)(p13;q11) [Case List]    t(12;17)(p13;q11) [Association List] Mitelman database (CGAP - NCBI)
arrayMapTopo ( C42) Morph ( 9811/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaset(12;17)(p13;q11-21) in ALL
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:55:33 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.